anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: The goal of this study was to describe the nightly sleep conditions of youth experiencing homelessness, and examine the association between sleep and mental health, both cross-sectionally and using diary data.
METHODS: n = 147 youth (ages 16-24) experiencing homelessness completed a baseline survey assessing self-reported sleep and depressive and anxious symptoms. A subsample of n = 49 completed a follow-up 7-day diary study measuring nightly sleep conditions and daily depressive and somatic symptoms.
RESULTS: According to baseline data, the majority of the sample (71%) reported sleeping less than 7 hours per night on average, and feeling like they did not get adequate sleep, especially among youth identifying as LGBTQ. In a qualitative follow-up question, the plurality attributed poor sleep to mental health woes. Cross-sectionally, youth with lower levels of self-reported sleep quality (more daytime fatigue and insomnia) reported higher levels of depressive and anxious symptoms. The diary data indicated that the most common nightly complaints among shelter utilizers are lack of privacy, noise, and uncomfortable temperatures. Multilevel models suggest that poor sleep conditions predicted higher levels of somatic symptoms the following day, after controlling for baseline levels of depressive and anxious symptoms.
CONCLUSIONS: This study highlights the role environmental context plays in sleep health and its subsequent impacts. Individuals experiencing homelessness lack autonomy over their sleeping environments, and thus cannot make adjustments such as reducing disruptions such as noise, temperature, and light. Importantly, these less-than-ideal sleeping conditions contribute to pre-existing health disparities and may have long-term implications.
A photosensitizing-remineralizing agent mixture was prepared by adding pre-green dye (0.05ml) to 1 mg of the assigned remineralizing agents. The diode laser was irradiated immediately with Average power of 1 W, Exposure time of 10 s, diode 810 nm, continuous and non-contact mode, and Irradiation speed of 1mm/ sec.
Continuity of care is a concept that has been garnering increased attention in the last few years. There have been multiple methods proposed by researchers for measuring continuity of care, most of which are based on proportions or ratios of visits to the same health care provider or centre. While a consistent method for measuring continuity of care is lacking, increased continuity of care using various definitions and measurement tools has been related to better well being, lower health care costs, better glucose control, and higher satisfaction but has also not been found to improve health outcomes in other scenarios. Whether a patient is better served by high sequential access to one provider or any provider within the same system or management team is controversial. Finally, patients' perceptions of continuity of care have not been generally evaluated or correlated with current measurement methods. This project was conducted with patients at the Group Health Centre in Sault Ste Marie, Ontario, a multi-disciplinary, multi-specialty health services organization serving 44,000 rostered patients
The present utility model relates to a formula which has beneficial impact on neurodegenerative diseases, in particular Alzheimer-type dementia, and consists of the following (in percept by weight): bioactive mucilage extract of the garden snail Helix aspersa: from 25.0 to 50.0 wt. %; vitamin mix: from 5.0 to 7.0 wt. %; excipients and stabilizers: from 45.0 to 67.5 wt. %; preservative agent: from 0.1 to 0.25 wt. % and deionized water up to 100 wt. %. The formula according to the present utility model has beneficial impact on the memory function due to its effects on oxidative stress, inflammation and cerebral mediation, and enhances the mental focus and concentration owing to its complex mechanism of neuroprotective action against Alzheimer-type dementia.
The present invention relates to an online mind-altering substance testing system. The system includes distributed mind-altering substance testing units for performing mind-altering substance tests. A server is provided for receiving results of the mind-altering substance tests. A database is provided for storing the results. A display is provided for displaying the stored results, preferably in a dashboard of graphs to facilitate rapid and intuitive evaluation of often large numbers of tests from various testing units. Advantageously, a reviewer may review live stored results from multiple testing units once the tests have been performed, which enables rapid risk assessment and corrective action to be undertaken. For example, the effect of failed tests may be more frequent at a certain site prompting a need for investigating a cause at that site.
Kit for the Preparation of Technetium Tc99m Sestamibi Injection is supplied as a 10 mL vial in kits of five (5) (NDC # 69945-092-20) or a carton of thirty (30) (NDC # 69945-092-40), sterile and non-pyrogenic. 

The patient dose should be measured by a suitable radioactivity calibration system immediately prior to patient administration. Radiochemical purity should be checked prior to patient administration.  


Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.  


Prior to lyophilization the pH is between 5.6-5.7. The contents of the vial are lyophilized and stored under nitrogen. Store at 15-25°C (59-77°F) before and after reconstitution. Protect from light prior to reconstitution.  
Technetium Tc99m Sestamibi contains no preservatives. Included in each five (5) vial kit is one (1) package insert and five (5) radioassay information labels with radiation warning symbol. Included in each thirty (30) vial carton is one (1) package insert and thirty (30) radioassay information labels with radiation warning symbol.

This reagent kit is approved by the U.S. Nuclear Regulatory Commission for distribution to persons licensed to use by-product material identified in §35.200 to 10 CFR Part 35, to persons who have a similar authorization issued by an Agreement State, and, outside the United States, to persons authorized by the appropriate authority.
The present invention discloses a medicine for treating leukoderma and a preparing method thereof. The existing medicines for treating leukoderma have the defects of slow effect, long treating time, etc. Some medicine has side effects. According to the cause of disease, the present invention aims at achieving the functions of sucking wind, eliminating toxicity, promoting blood circulation and nourishing livers and kidneys. Ingredients are added on the basis of the ingredients, such as rehmannia root, prepared rhizome of rehmannia, Chinese teasel root, saute bombyx batryticatus, aspongopus, typhonii, angelica, white peony root, bupleurum root, baked fleece-flower root, Chuanxiong rhizome, eupolyphaga, kakuda figwort root, tribulus terrestris, zedoary turmeric root-tuber, lily, radix adenophorae, honeysuckle flower, tangerine peel, glossy privet fruit, resina draconis, etc., to be formed into serial medicines for treating leukoderma. Through clinical verification, the present invention has a quick effect; the state of illness is controlled in 1 to 4 weeks; the curing rate is 87% to 94%, and the present invention is a good medicine which is worth being generalized.
The present disclosure relates to a liquid agent and/or hair dye for oxidative coloring of keratinous fibers with improved color performance and nourishing effect. In an embodiment, the agent comprises, in a hydrous cosmetic carrier: (a) a fatty acid which is liquid at 20° C. and has about 16-22 carbon atoms in an amount of about 0.1-15 wt. %, (b) an alkanolamine as an alkalizing agent, selected from monoethanolamine, 2-amino-2-methylpropanol and triethanolamine, in an amount such that at least one part of the fatty acid is present as soap, (c) an oil component different from (a) in an amount of about 0.05-5 wt. %, (d) an alkylamidoamine in an amount of about 0.05-6 wt. %, and (e) an oxidation dye precursor. The agent does not contain any branched fatty alcohols having about 7 or more carbon atoms, and does not contain any fatty alcohols having a melting point of about 25° C. or higher.
Keratitis, characterized as acute or worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain, and/or red eye occurred in 0.7% of patients treated with GILOTRIF among 4257 patients across clinical trials, of which 0.05% of patients experienced Grade 3 keratitis. Keratitis was reported in 2.2% patients in LUX-Lung 3, with Grade 3 in 0.4%. In LUX-Lung 8, keratitis was reported in 0.3% patients; there were no patients with ≥Grade 3 keratitis.

Withhold GILOTRIF during evaluation of patients with suspected keratitis, and if diagnosis of ulcerative keratitis is confirmed, interrupt or discontinue GILOTRIF [see Dosage and Administration (2.3)]. If keratitis is diagnosed, the benefits and risks of continuing treatment should be carefully considered. GILOTRIF should be used with caution in patients with a history of keratitis, ulcerative keratitis, or severe dry eye [see Adverse Reactions (6.1)]. Contact lens use is also a risk factor for keratitis and ulceration.
Cohort of 50 patients with CKD of known cause Inclusion and exclusion criteria below Measure of arterial stiffness using pulse wave velocity technology Assessment of BMI, central and brachial blood pressure, arterial stiffness and 'arterial age' will be made and fed back to the patient. this information will be given in a 'results sheet' that the participant will be encouraged to give to their Gp for further treatments required.
Nasal and inhaled corticosteroids may result in the development of glaucoma and/or cataracts. Therefore, close monitoring is warranted in patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts.

Glaucoma and cataract formation were evaluated with intraocular pressure measurements and slit lamp examinations in a controlled 12-month study in 612 adolescent and adult patients aged 12 years and older with perennial allergic or vasomotor rhinitis (VMR). Of the 612 patients enrolled in the study, 405 were randomized to receive DYMISTA (1 spray per nostril twice daily) and 207 were randomized to receive fluticasone propionate nasal spray (2 sprays per nostril once daily). In the DYMISTA group, one patient had increased intraocular pressure at month 6. In addition, three patients had evidence of posterior subcapsular cataract at month 6 and one at month 12 (end of treatment). In the fluticasone propionate group, three patients had evidence of posterior subcapsular cataract at month 12 (end of treatment).
PURPOSE:To improve shape retention and decrease water sepn. by compounding respectively specified ratios of emulsifiers such as 1, water soluble polyglycerol fatty acid ester 2, monoglycerol fatty acid ester and sorbitan fatty acid ester. CONSTITUTION:An oil phase component is prepd. by adding the emulsifier such as monoglycerol fatty acid ester having >=30 iodine number to lipid having >=45wt% solid fat ratio at 10 deg.C at 3-15wt% by the weight of the oil phase component. The water soluble polyglycerol fatty acid ester is added and dis solved therein at 0.05-1.0wt% of the water phase component to prepare the water phase component. 70-39wt% water phase component (by the weight of the final product) and 7-30wt% oil phase component (by the weight of the final product) are mixed. The mixture is preliminarily emulsified and homog enized and is then quickly cooled, by which the average grain size of the fat cells of the oil-in-water type emulsion is adjusted to <=0.5mu and the solid oil-in- water type emulsion is produced.
The present invention relates to a medical pill (Yuganwan) which belongs to Chinese patent medicine. The present invention is used for treating various kinds of hepatitis, child anorexia, etc. The present invention is characterized in that the present invention is prepared from traditional Chinese medicine such as cortex moutan, lespedeza, bupleurum roots, angelica, radix paeoniae alba, rhizoma, tuckahoe, liquorice, mint, turtle shells, magnolia barks, preserved prune, etc. Pilose asiabell roots, oyster, grifola, trogopterus dung, malt, red sage roots, rehmannia roots, scrophularia roots, radix adenophorae, lilyturf roots and tortoise plastron can also be added in raw materials for patients with limb pyrexia, heart pyrexia, dry mouths and dry eyes. The raw materials are mixed according to a certain portion, and are added with honey to be refined into a pill. The present invention has the advantages of simple and convenient recipe process and application method, pure Chinese medical preparation, no toxic side effect, low price, availability for various kinds of hepatitis and child anorexia, etc.
The present invention belongs to the field of nanoporous materials, in particular metal organic frameworks (MOFs) and Lewis-based gas delivery and/or slow release, or the detection of Lewis-based gas(es) in gases or liquid streams. The present invention relates, inter alia, to a new ultra-microporous crystalline metal organic framework solid ( comprising bisphosphonic acid ligands (also refered to as Phosphonate MOF), such as MIP-210(M) and uses thereof as a carrier in Lewis-based gas (such as NO) delivery. The invention also relates to controlled release of the Lewis-based gas in wounds, for example by topical application. The invention also encompasses a synthetic method for producing the new ultra- microporous crystalline metal organic framework solid of the invention. The MOFs of the present invention can be used in various applications such as gas carrier and/or for the controlled release of gas. The MOFs of the present invention thus are very versatile and have therapeutic and non therapeutic applications.
The study will involve a randomized, double blind, non-inferiority clinical trial with two treatment arms conducted in two international academic medical centers (the Centre for Addiction and Mental Health in Toronto, Canada and UT Southwestern in Dallas, Texas). The investigators are pursuing a non-inferiority clinical trial in an effort to compare MST - a new treatment for TRD - to RUL-UB-ECT. Treatment will be administered two to three days per week. Depression symptoms will be assessed with the 24-item Hamilton Depression Rating Scale (HRSD-24) and suicidality will be assessed with the Scale for Suicidal Ideation (SSI). Remission will be defined as HRSD-24 \< or = 10 and a \> 60% decrease in scores from baseline on two consecutive ratings. Once a participant reaches remission, a second rating to confirm remission will be conducted immediately before their next scheduled treatment. If remission is confirmed, they will then be considered a completer of the acute treatment course. Remission of suicidal ideation is defined as a score of 0 on the SSI. Therefore, there will be no specific minimum number of treatments that patients must receive to be classified as remitters. However, patients who do not meet remission criteria after 21 treatment sessions will be considered non-remitters and will cease treatment sessions. This maximum treatment number was chosen allowing for the possibility that MST may require more treatment sessions to achieve remission, similar to RUL-UB ECT. The blind will not be broken to participants until the completion of the entire study.
After 24 weeks of treatment with pegylated interferon alfa-2a (PEG-IFN alfa-2a) 180 μg/week plus ribavirin 800-1200 mg/day participants who achieved at least a 2-log10 drop of hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 12 (as compared to HCV RNA levels prior to treatment initiation) or had HCV RNA \<15 IU/mL, and who were still taking study medication at treatment Week 24 were randomized into the study, at which time treatment was stopped. Participants were followed for an additional 48 weeks during the treatment-free follow-up period.
The present invention provides for a process for preparing liposomes, lipid discs, and other lipid nanoparticles using a multi-port manifold, wherein the lipid solution stream, containing an organic solvent, is mixed with two or more streams of aqueous solution (e.g., buffer). In some aspects, at least some of the streams of the lipid and aqueous solutions are not directly opposite of each other. Thus, the process does not require dilution of the organic solvent as an additional step. In some embodiments, one of the solutions may also contain an active pharmaceutical ingredient (API). This invention provides a robust process of liposome manufacturing with different lipid formulations and different payloads. Particle size, morphology, and the manufacturing scale can be controlled by altering the port size and number of the manifold ports, and by selecting the flow rate or flow velocity of the lipid and aqueous solutions.
Disclosed is the use of paliperidone palmitate in the treatment of psychosis, schizophrenia, bipolar disorder, or other mental disorder according to a dosing regimen comprising: a) administering intramuscularly in the deltoid of a patient a first loading dose of from about 100 mg-eq. to about 150 mg-eq. of paliperidone palmitate formulated in a sustained release formulation on the first day of treatment; b) administering intramuscularly in the deltoid muscle of the patient in need of treatment a second loading dose of from about 100 mg-eq. to about 150 mg-eq. of paliperidone palmitate formulated in a sustained release formulation on the 6th to about 10th day of treatment; and c) administering intramuscularly in the deltoid or gluteal muscle of the patient in need of treatment a maintenance dose of about 25 mg-eq. to about 150 mg-eq. of paliperidone palmitate in a sustained release formulation on about the 34th to about the 38th day of treatment.
A series of medically tailored meals appropriate for women with gestational diabetes will be developed in partnership with chefs from a local community kitchen and catering company. Meals will create a slight caloric deficit in order to promote gradual weight loss, but with sufficient energy intake and macronutrient balance to allow breastfeeding. These meals will be roughly 40% carbohydrate, 30% protein, and 30% fat in composition. Study Team will plan up to 20 unique lunch and dinner meals for the series. Each meal will be prepared to be between 450-600 kcal and to contain 6 ounces of protein, 4 ounces of vegetable and I cup of whole grain (at a minimum). Participants will receive detailed recipe cards and nutrition information with each meal. In addition to receiving the medically tailored meals, participants will be advised to supplement their own breakfast +/- snacks to reach a total daily calorie goal determined by starting BMI category.
INTRODUCTION: Although the enhanced-view totally extraperitoneal (eTEP) approach has demonstrated safety, efficacy, and durability for small- to medium-sized hernia repairs, the relationships between retrorectus insufflation, intraoperative respiratory stability, and end-tidal CO2 (ETCO2) levels has not been appraised.
METHODS: We conducted a retrospective chart review of patients undergoing elective robotic-assisted ventral hernia repairs at our quaternary academic center from July 2018 through December 2021. Patients were grouped by repair technique, either eTEP or robotic transversus abdominis release (r-TAR). Baseline demographics, intraoperative anesthesia records, and perioperative outcomes were reviewed. Anesthesia data were collected at intubation and 30-min time intervals thereafter. Operative time, length of stay, patient-controlled anesthesia use, and perioperative complications were compared.
RESULTS: In total, 205 patients underwent an eTEP repair and 97 patients underwent an r-TAR repair. Intraoperatively, eTEP repairs had significantly higher ETCO2 at the beginning of the case (times 1-4, P < 0.05), and a higher peak ETCO2 (P < 0.05) when compared to r-TAR repairs. This difference in ETCO2 desisted as the case progressed, with a subsequent increase in respiratory rate (times 2-6, P < 0.05) in the eTEP procedures. The eTEP group demonstrated significantly shorter operative times, decreased patient-controlled anesthesia use, and a shorter length of stay. There was no significant difference in postoperative intensive care unit admission or respiratory distress.
CONCLUSIONS: This study demonstrates that retrorectus insufflation during eTEP hernia repairs correlated with higher levels of ETCO2 compared to r-TAR repairs yet was not associated with any meaningful difference in perioperative outcomes. Communication of these respiratory differences with anesthesia is needed for proper ventilation adjustments.
UNLABELLED: This study aimed to comprehensively analyze inflammatory and autoimmune characteristics of patients with sickle cell disease (SCD) at a steady-state condition (StSt) compared to healthy controls (HCs) to explore the pathogenesis of StSt and its impact on patients' well-being. The study cohort consisted of 40 StSt participants and 23 HCs enrolled between July 2021 and April 2023. StSt participants showed elevated white blood cell (WBC) counts and altered hematological measurements when compared to HCs. A multiplex immunoassay was used to profile 80 inflammatory cytokines/chemokines/growth factors in plasma samples from these SCD participants and HCs. Significantly higher plasma levels of 35 analytes were observed in SCD participants, with HGF, IL-18, IP-10, and MCP-2 being among the most significantly affected analytes. Additionally, autoantibody profiles were also altered, with elevated levels of anti-SSA/Ro60, anti-Ribosomal P, anti-Myeloperoxidase (MPO), and anti-PM/Scl-100 observed in SCD participants. Flow cytometric analysis revealed higher rates of red blood cell (RBC)/reticulocyte-leukocyte aggregation in SCD participants, predominantly involving monocytes. Notably, correlation analysis identified associations between inflammatory mediator levels, autoantibodies, RBC/reticulocyte-leukocyte aggregation, clinical lab test results, and pain crisis/sensitivity, shedding light on the intricate interactions between these factors. The findings underscore the potential significance of specific biomarkers and therapeutic targets that may hold promise for future investigations and clinical interventions tailored to the unique challenges posed by SCD. In addition, the correlations between vaso-occlusive crisis (VOC)/pain/sensory sensitivity and inflammation/immune dysregulation offer valuable insights into the pathogenesis of SCD and may lead to more targeted and effective therapeutic strategies.
CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, Identifier: NCT05045820.
Patients presenting with \<= 20 degrees of abduction on a maximum abduction x-ray treated with bracing who also present in the late stages of the disease (Waldenstrom Stage IIb or IIIa).The choice of management with or without containment or surgical containment would be solely governed by the current practice of the participating surgeons (i.e. the current practice of the individual surgeon would be followed within the broad framework of the study).
The invention relates to a simvastatin tablet preparation method, and belongs to the field of statin medicine tablet preparation methods. The tablets are composed of simvastatin and auxiliary materials such as a filling material, an adhesive, a disintegrant, an antioxidant, a lubricant, and the like. The method is characterized in that compressible starch is adopted as the adhesive and the disintegrant, and the mass ratio of simvastatin to the compressible starch is 1: (0.5-1.5). The invention mainly solves a problem of simvastatin tablet dissolution stability, such that simvastatin dissolution curve is S-shaped. During dissolution, an in-vitro slow intermediate-release characteristic is shown. The release characteristic satisfies clinical requirements, and assists in providing a good hypolipidemic effect. The preparation method provided by the invention has the advantages of simple process, feasible operation, and suitability for large-scale productions.